CureVac and Rentschler ramp up CVnCoV production

1 February 2021

Clinical-stage German biotech CureVac’s (Nasdaq: CVAC) shares were up more than 10% in pre-market New York trading today, after it announced initiating the set-up of manufacturing capabilities for its3 COVID-19 vaccine, CVnCoV, with contract manufacturer Rentschler Biopharma.

Rentschler is gearing up for largescale current Good Manufacturing Practice (cGMP) production of the formulated mRNA for CVnCoV. CureVac has started the clinical Phase IIb/III trial with its mRNA-based vaccine candidate against SARS-CoV-2, and therefore, is preparing the start of commercial production to meet global demands. Rentschler contributes to the manufacturing of active pharmaceutical ingredient, downstream processing and formulation of drug substance for the vaccine.

The companies entered into a collaboration in November 2020 with the set-up of dedicated production lines at the Rentschler site in Laupheim, Germany. Currently, optimization of the production process is taking place to increase mRNA yield. It is expected to produce more than 100 million doses of the CureVac vaccine per year in Laupheim.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK